Medtronic has launched its MiniMed Go Smart MDI system with the Simplera sensor in Europe.

According to the company, the system is the first and only solution to integrate data from the InPen smart insulin pen and the Simplera sensor into one mobile app, which was designed to help those using multiple daily injections (MDI) to better control their diabetes.

The launch will take place gradually across Europe beginning this month. The Smart MDI system with Abbott’s Instinct sensor won U.S. Food and Drug Administration (FDA) clearance last month.

The MiniMed Go Smart MDI system provides real-time, personalized insights, actionable dose alerts, a built-in advanced dose calculator, and continuous guidance. These are all accessible through a smartphone app—the intelligent support tool seeks to address daily challenges of those managing diabetes with MDI.

Real-world data from the previous generation of the Smart MDI system showed that users who responded to over 75% of missed dose alerts within one hour achieved Time in Range (TIR) of 67.2% compared to the mean TIR for the cohort at 55.7%, and up to 71.5% TIR when addressing high blood sugar alerts.

“Real-time actionable alerts are becoming the key to better clinical outcomes for people with diabetes using multiple daily injections,” said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. “The MiniMed Go system remembers, reminds and recommends the right dose at the right time so you don´t have to.”

The system also includes new CareLink Clinic MDI reports, which the company said makes it easier for clinicians to interpret user data and support more informed patient decisions.

“Smart MDI has fundamentally changed how we care for patients on multiple daily injections,” said Dr. Martín Cuesta Hernández, Endocrinologist, Hospital Clinico San Carlos, Madrid, Spain. “We’re now making evidence-based decisions instead of relying on assumptions, which has strengthened trust and improved the quality of our conversations with patients. Many people simply tell us they’re delighted because life is easier. Combined with efficient telemedicine delivery, we’re able to provide more personalized, effective care than ever before.”

In Europe, the system is approved for patients with insulin-requiring diabetes aged seven years and older, as well as children aged two to six years under an adult caregiver’s supervision. Compatibility of Abbott’s Instinct Go sensor with MiniMed Go in Europe is currently pending CE mark approval.